Expect a Limited Role for Zurzuvae for Postpartum Depression

February 2024

New Rx zuranolone (Zurzuvae) will be the first ORAL med approved for treatment of postpartum depression.

Think of it as similar to IV brexanolone (Zulresso).

Both mimic the hormone allopregnanolone, which interacts with GABA receptors. This hormone abruptly dips around childbirth...possibly leading to major depression.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: PA includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote